CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Azilsartan medoxomil + chlorthalidone

Last Updated: March 8, 2013
Result type: Reports
Project Number: SR0318-000
Product Line: Reimbursement Review

Generic Name: Azilsartan medoxomil + chlorthalidone

Brand Name: Edarbyclor

Manufacturer: Takeda Canada Inc.

Therapeutic Area: Hypertension

Indications: Hypertension, essential

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 17, 2013

Recommendation Type: Do not list